Glaukos reported second-quarter revenue of $95.69 million, a 19% increase from the same period last year, surpassing the Zacks Consensus Estimate of $88.41 million by 8.24%. The company posted a net loss of $0.52 per share, matching analyst expectations and narrowing from a loss of $0.55 per share a year ago. Within the United States, glaucoma revenue reached $49.75 million, up 25.6% year over year and above the $44.75 million estimate, while corneal health revenue in the U.S. was $17.07 million, a 4.7% increase that slightly exceeded the $17.04 million consensus. International revenue totaled $28.87 million, growing 17.9% and beating the $26.24 million estimate, with international glaucoma revenue of $26.13 million and international corneal health revenue of $2.74 million both topping projections. Overall, glaucoma revenue was $75.90 million, up 22.6%, and corneal health revenue was $19.80 million, up 7.1%, each ahead of analyst forecasts.
Glaukos CorpRevenue beat estimates and net loss narrowed, indicating strong financial performance.